
Valink Therapeutics
Valink Therapeutics is a YC Winter 2021 (W21) company. Based in Boston, MA, USA. Team of 15.
About Valink Therapeutics
Summary
Valink Therapeutics develops bispecific antibody-drug conjugates targeting solid tumors that respond poorly to existing immunotherapy. Its proprietary LiliumX platform combines synthetic protein biology, high-throughput functional screening, and AI to generate complex drug candidates, incorporating bispecificity, multivalency, and drug conjugation in a single discovery process. This replaces the sequential, siloed engineering steps conventional ADC programs require, and its V-Gate mechanism tunes therapeutic binding to continuous levels of two tumor-surface targets rather than simple on/off logic.
From the Y Combinator listing
Discovering bispecific antibody drug-conjugates (BsADC) against cancer
Valink Therapeutics develops next generation antibody-based therapeutics. We identify novel mechanism of action from known targets by incorporating multiple antibody modifications at once, rapidly and scalable generating complex drug candidates (bi-/multispecificity, multivalency and drug-conjugation in a single discovery process). Our research focus is on solid tumours poorly addressed by immunotherapy.
Facts
- Healthcare / Healthcare -> Therapeutics
- Boston, MA, USA
- 15
- Active
- Early
Founders (2)
- Arne Scheu
- Irsyad Khairil
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works